A Network Meta-Analysis of Two Doses of Recombinant Human Thrombopoietin for Treating Sepsis-Related Thrombocytopenia
Previous studies suggest that sepsis remains a common critical illness with a global incidence of 31.5 million. The aim of this study was to evaluate the comparative therapeutic value of recombinant human thrombopoietin (rhTPO) in treating sepsis patients with thrombocytopenia. We conducted a compre...
Saved in:
| Main Authors: | Dandan Chen, Yu Hou, Chaochao Wei, Xingjun Cai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | International Journal of Clinical Practice |
| Online Access: | http://dx.doi.org/10.1155/2022/2124019 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and Safety of Recombinant Human Thrombopoietin (rhTPO) on Coagulation Function and Inflammatory Factors in the Treatment of Patients with Sepsis-Related Thrombocytopenia
by: Huijuan Wang MD, et al.
Published: (2025-02-01) -
Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)Research in context
by: Yunfei Chen, et al.
Published: (2025-09-01) -
Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2017-11-01) -
Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2024-04-01) -
Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?
by: Hanny Al-Samkari
Published: (2025-07-01)